4.7 Article

Development of selective class I protein arginine methyltransferase inhibitors through fragment-based drug design approach

期刊

出版社

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2023.115713

关键词

PKMTs; PRMTs; Selective inhibitors; Fragment -based drug design

向作者/读者索取更多资源

Protein arginine methyltransferases (PRMTs) play a crucial role in the methylation of arginine groups in protein substrates, and dysregulated expression of these enzymes is associated with various diseases. Development of PRMT inhibitors has shown promise as a therapeutic strategy, and small fragment inhibitors have been identified as potential starting points for drug development. In this study, a fragment-based approach was used to discover selective Class I PRMT inhibitors, and lead compounds 55 and 56 displayed potent inhibition of PRMT4. These findings provide new options for the development of potent and selective PRMT4 inhibitors.
Protein arginine methyltransferases (PRMTs) catalyze the methylation of the terminal nitrogen atoms of the guanidino group of arginine of protein substrates. The aberrant expression of these methyltransferases is linked to various diseases, making them promising therapeutic targets. Currently, PRMT inhibitors are at different stages of clinical development, which validated their significance as drug targets. Structural Genomics Consortium (SGC) has reported several small fragment inhibitors as Class I PRMT inhibitors, which can be the starting point for rational drug development. Herein, we report the successful application of a fragment-based approach toward the discovery of selective Class I PRMT inhibitors. Structure-based ligand optimization was performed by strategic incorporation of fragment hits on the drug-like quinazoline core and subsequent fragment growth in the desired orientation towards identified hydrophobic shelf. A clear SAR was established, and the lead compounds 55 and 56 displayed potent inhibition of Class I PRMTs with IC50 values of 92 nM and 37 nM against PRMT4. We report the systematic development of potent Class I PRMT inhibitors with good potency and about 100-fold selectivity when tested against a panel of 31 human DNA, RNA, and protein lysine and arginine methyltransferases. These improved small molecules will provide new options for the development of novel potent and selective PRMT4 inhibitors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据